BioSpace News Archive

Restore Hyper Wellness + Cryotherapy (Restore), a leading retail provider of health and wellness services, today announced the opening of Restore Labs, its new research and development facility.

Economic activity in the manufacturing sector grew in February, and the overall economy grew for the 130th consecutive month, say the nation’s supply executives in the latest Manufacturing ISM® Report On Business®.

Longhorn Vaccines & Diagnostics, announced today that the U.S. Food and Drug Administration (FDA) has recommended that the company collaborate with diagnostic assay manufacturers to ensure that Longhorn’s PrimeStore MTM® is included as a transport device in Emergency Use Authorization (EUA) applications submitted to the FDA for research samples for the Coronavirus disease 2019 (COVID-19).

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA” (TSX VENTURE: IPA) (OTC QB: IPATF), through its subsidiary, Talem Therapeutics (talemtherapeutics.com), and the New York-based company EVQLV, Inc. (evqlv.com), announces a new collaboration aimed at accelerating the global effort to develop lead therapeutic and vaccine candidates against the SARS-CoV-2 virus.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it will report its fourth quarter and full year 2019 financial results on Monday, March 9, 2020.

Quantum-Si, a Connecticut-based start-up, today introduced the world’s first next-generation protein sequencing platform at Cowen Healthcare 2020

VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of patient enrollment in a Phase 4 clinical study designed to evaluate the safety and efficacy of Qsymia® (phentermine and topiramate extended-release) capsules CIV in adolescents between the ages of 12 and 17 years who are obese (NCT# 03922945).

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2019.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ending December 31, 2019, and provided a corporate update.

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided a corporate update.